Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 2/20 | 0.36 |
| ▸ | CPA3 | P15088 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610943 | 0.88 | FOLH1 (0.43) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL14558137 | 0.84 | CYP1A2 (0.47) | CYP1A2FOLH1 | |
| SCHEMBL14558136 | 0.82 | FOLH1 (0.45) | CYP1A2FOLH1CPA3HTR2AADRA1A | |
| SCHEMBL14558096 | 0.80 | HPGD (0.48) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL252900 | 0.76 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL629350 | 0.76 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL9007628 | 0.76 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL5096045 | 0.76 | PTGS2 (0.51) | CYP1A2FOLH1PTGS2CPA1CPA3 | |
| SCHEMBL26732440 | 0.74 | AKR1B1 (0.46) | CYP1A2ADRA2BADRA2CSLC6A2HTR2A | |
| SCHEMBL22388384 | 0.73 | ADRA2B (0.46) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | CYP1A2 2606/4885FOLH1 4018/4885PTGS2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.